TRAVOPROST Drug Patent Profile

Which patents cover Travoprost, and when can generic versions of Travoprost launch?

Travoprost is a drug marketed by Alembic, Apotex, Chartwell Rx, Gland, Lupin Ltd, Micro Labs, Mylan, and Somerset Theraps Llc. and is included in nine NDAs.

The generic ingredient in TRAVOPROST is travoprost. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the travoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Travoprost

A generic version of TRAVOPROST was approved as travoprost by CHARTWELL RX on March 1^st, 2013.

Summary for TRAVOPROST

US Patents:	0
Applicants:	8
NDAs:	9
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	107
Patent Applications:	4,867
Drug Prices:	Drug price information for TRAVOPROST
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRAVOPROST
DailyMed Link:	TRAVOPROST at DailyMed

See drug prices for TRAVOPROST

See drug sales revenues for TRAVOPROST

Recent Clinical Trials for TRAVOPROST

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Salus University	Phase 4
Glaukos Corporation	PHASE2
Assiut University	Phase 4

See all TRAVOPROST clinical trials

Pharmacology for TRAVOPROST

Drug Class

Prostaglandin Analog

Medical Subject Heading (MeSH) Categories for TRAVOPROST

Antihypertensive Agents

Anatomical Therapeutic Chemical (ATC) Classes for TRAVOPROST

S01EE	Prostaglandin analogues
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for TRAVOPROST

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IZBA	Ophthalmic Solution	travoprost	0.003%	204822	1	2015-12-30
TRAVATAN Z	Ophthalmic Solution	travoprost	0.004%	021994	1	2009-02-19
TRAVATAN	Ophthalmic Solution	travoprost	0.004%	021257	1	2008-11-28

US Patents and Regulatory Information for TRAVOPROST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	TRAVOPROST	travoprost	SOLUTION/DROPS;OPHTHALMIC	210458-001	Dec 20, 2019		DISCN	No	No
Micro Labs	TRAVOPROST	travoprost	SOLUTION/DROPS;OPHTHALMIC	203767-001	Mar 19, 2021	AT2	RX	No	No
Chartwell Rx	TRAVOPROST	travoprost	SOLUTION/DROPS;OPHTHALMIC	091340-001	Mar 1, 2013		RX	No	Yes
Mylan	TRAVOPROST	travoprost	SOLUTION/DROPS;OPHTHALMIC	205050-001	Jul 7, 2017	AT2	RX	No	No
Alembic	TRAVOPROST	travoprost	SOLUTION/DROPS;OPHTHALMIC	214687-001	Dec 17, 2025	AT2	RX	No	No
Apotex	TRAVOPROST	travoprost	SOLUTION/DROPS;OPHTHALMIC	203431-001	Jul 10, 2015	AT2	RX	No	No
Lupin Ltd	TRAVOPROST	travoprost	SOLUTION/DROPS;OPHTHALMIC	207040-001	May 3, 2024		DISCN	No	No

EU/EMA Drug Approvals for TRAVOPROST

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Izba	travoprost	EMEA/H/C/002738Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.	Authorised	no	no	no	2014-02-20
Novartis Europharm Limited	Travatan	travoprost	EMEA/H/C/000390Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).	Authorised	no	no	no	2001-11-27

Market Dynamics and Financial Trajectory for Travoprost

Last updated: February 19, 2026

Travoprost, a prostaglandin analog used to treat glaucoma and ocular hypertension, shows steady clinical adoption driven by its efficacy and safety profile. Its market growth aligns with increasing prevalence of glaucoma globally. The drug's financial trajectory suggests moderate revenue stability with potential growth from new formulations and expanded indications.

Market Size and Growth Drivers

Global Glaucoma Market Overview

The global glaucoma treatment market was valued at approximately USD 5.8 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of around 4.5% from 2023 to 2030, reaching an estimated USD 8.7 billion by 2030 (Grand View Research, 2022). The growth is driven by an aging population, improved diagnostic methods, and rising awareness of ocular health.

Travoprost Market Share

Travoprost accounts for an estimated 12-15% of the glaucoma medication market share in developed regions. Its primary competitors include latanoprost, bimatoprost, and tafluprost. The drug's advantages over competitors are its comparable efficacy and potentially lower intraocular pressure (IOP) fluctuations.

Regional Market Penetration

North America dominates with a share exceeding 45%, attributable to high prevalence, advanced healthcare infrastructure, and patent protections. Europe holds roughly 25%, while Asia-Pacific, experiencing fast growth, accounts for about 20% of the market. Emerging markets in Latin America and Africa lag, but show increasing adoption.

Product Pipeline and Innovation

Formulation Developments

Recent innovations include preservative-free formulations and combination therapies, which improve patient compliance. Notably, the introduction of fixed-dose combinations with other ocular hypotensives aims to expand market size by targeting patients with more severe glaucoma or requiring multi-drug regimens.

Patent and Exclusivity

As of 2023, travoprost’s primary patent protections extended into 2026, with some formulations having earlier expiry dates. Patent expirations typically lead to increased competition from generics, which can impact revenue trajectories.

Revenue and Financial Outlook

Historical Revenue Data

Major pharmaceutical companies producing travoprost (e.g., Allergan, Santen) report annual global sales in the range of USD 200-300 million for branded formulations. For instance, Allergan's optic products indicated USD 250 million in 2022 (company annual report).

Projected Revenue Trends

Post-patent expiry, generic competition is expected to reduce branded revenues by up to 70%. However, continued growth in the glaucoma market and expanded indications could mitigate declines through volume increases. Sales of preservative-free and combination formulations are expected to boost growth by around 6-8% annually in the next five years.

Impact of Market Entry Strategies

Companies employing aggressive marketing, strong distribution networks, and investments in patient adherence programs can sustain or increase revenue despite generic competition. Increased adoption in developing countries further enhances revenue prospects.

Competitive Landscape

Company	Product Name	Market Share	Key Strategies	Patent Status
Allergan (AbbVie)	Travatan Z	High	Brand loyalty, global distribution	Patent until 2026
Santen	Vyzulta (combination)	Moderate	Formulation innovation	Patent until 2024
Others	Generic versions	Growing	Price competition, expanded access	Patent expired or pending

Genuine market growth depends on innovation, patent protections, and regulatory pathways for new formulations.

Regulatory Environment

Approvals and Reimbursements

Regulatory approvals for travoprost are well-established in the US, EU, and Japan. Reimbursements policies favor preserved and preservative-free formulations. Changes in healthcare reimbursement schemes can influence sales volumes.

Patent Litigation and Conflicts

Patent disputes from generic manufacturers can delay or limit the entry of biosimilars, shaping revenue trajectories. Patent litigation in key markets remains active through 2025, influencing market stability.

Risks and Challenges

• Patent expiry leading to price erosion.
• Competition from alternative therapies like laser surgery and newer drugs.
• Regulatory delays for new formulations.
• Limited awareness and access in emerging markets.

Summary and Future Outlook

Travoprost will experience modest growth within the broader glaucoma market, driven by formulations innovation and expanded geographic reach. Emerging markets pose growth opportunities, but patent expirations and competition from generics stand as key risks. Market strategies focused on product differentiation and patient adherence will influence revenue trajectories.

---

Key Takeaways

• The global glaucoma market is expected to reach USD 8.7 billion by 2030, with travoprost holding a significant share.
• Revenue from branded travoprost has stabilized around USD 200-300 million annually and may decline post-patent expiry unless offset by formulation and market expansion.
• Patent protections extend until 2026, after which generic competition will intensify.
• Innovation in preservative-free and combination formulations supports growth.
• Regional dynamics heavily influence revenue, with North America leading, followed by Europe and Asia-Pacific.

---

FAQs

1. When does the main patent for travoprost expire?
In 2026, after which generic versions are expected to enter key markets.

2. What factors influence the adoption of travoprost in emerging markets?
Pricing, regulatory approval, healthcare infrastructure, and local disease prevalence.

3. How do new formulations impact the market?
They improve patient compliance, extend patent life, and open new revenue streams.

4. What are the primary competitors to travoprost?
Latanoprost, bimatoprost, tafluprost, and emerging combination therapies.

5. How might regulatory changes affect travoprost sales?
Reimbursement policy adjustments and approval pathways for generics directly influence market penetration.

---

References

1. Grand View Research. (2022). Glaucoma Treatment Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/
2. Allergan Annual Report. (2022). Financial reporting for ophthalmic products. Retrieved from company filings.
3. U.S. Food and Drug Administration. (2022). ANDA approvals and patent listings. Retrieved from https://www.fda.gov/
4. European Medicines Agency. (2022). Regulatory updates on glaucoma medications. Retrieved from https://www.ema.europa.eu/
5. Santen Pharmaceutical. (2023). Product pipeline and market strategy reports. Retrieved from official site.